IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11246873 B1

PDFFull Text
Date of Patent:
Feb. 15, 2022

Filed:

Apr. 08, 2020

Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate

Applicants:

The Scripps Research Institute, La Jolla, CA (US);

Novartis Ag, Basel, CH;

Inventors:

Peter Schultz, La Jolla, CA (US);

Luke Lairson, San Diego, CA (US);

Vishal Deshmukh, La Jolla, CA (US);

Costas Lyssiotis, Boston, MA (US);

Assignee:

The Scripps Research Institute, La Jolla, CA (US);

Attorney:

Kilpatrick Townsend & Stockton LLP

Primary Examiner:

Shengjun Wang

Int. Cl.
CPC ...
A61K 31/44 (2006.01); A61K 31/445 (2006.01); A61K 31/40 (2006.01); A61K 31/35 (2006.01); A61K 31/24 (2006.01); A61K 31/135 (2006.01); A61K 38/00 (2006.01); A61K 31/5415 (2006.01); A61K 31/439 (2006.01); A61K 31/138 (2006.01); A61K 31/137 (2006.01); A61K 38/21 (2006.01); A61K 39/395 (2006.01); A61K 31/216 (2006.01); A61K 31/46 (2006.01); A61K 31/495 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5415 (2013.01); A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/138 (2013.01); A61K 31/216 (2013.01); A61K 31/40 (2013.01); A61K 31/439 (2013.01); A61K 31/46 (2013.01); A61K 31/495 (2013.01); A61K 38/215 (2013.01); A61K 39/3955 (2013.01);
Abstract

The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

Find Patent Forward Citations

Loading…